These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 16389309)

  • 1. Knock-in mouse models of Huntington's disease.
    Menalled LB
    NeuroRx; 2005 Jul; 2(3):465-70. PubMed ID: 16389309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice.
    Hickey MA; Kosmalska A; Enayati J; Cohen R; Zeitlin S; Levine MS; Chesselet MF
    Neuroscience; 2008 Nov; 157(1):280-95. PubMed ID: 18805465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene-environment interactions, neuronal dysfunction and pathological plasticity in Huntington's disease.
    van Dellen A; Grote HE; Hannan AJ
    Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1007-19. PubMed ID: 16445565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175.
    Menalled LB; Kudwa AE; Miller S; Fitzpatrick J; Watson-Johnson J; Keating N; Ruiz M; Mushlin R; Alosio W; McConnell K; Connor D; Murphy C; Oakeshott S; Kwan M; Beltran J; Ghavami A; Brunner D; Park LC; Ramboz S; Howland D
    PLoS One; 2012; 7(12):e49838. PubMed ID: 23284626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntington's Disease.
    Peng Q; Wu B; Jiang M; Jin J; Hou Z; Zheng J; Zhang J; Duan W
    PLoS One; 2016; 11(2):e0148839. PubMed ID: 26859386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.
    Nithianantharajah J; Hannan AJ
    Neuroscience; 2013 Oct; 251():66-74. PubMed ID: 22633949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic mouse models of Parkinson's disease and Huntington's disease.
    Skaper SD; Giusti P
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):455-70. PubMed ID: 20522011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine Models of Huntington's Disease for Evaluating Therapeutics.
    Kosior N; Leavitt BR
    Methods Mol Biol; 2018; 1780():179-207. PubMed ID: 29856020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Huntington's disease: pathogenesis to animal models.
    Kumar P; Kalonia H; Kumar A
    Pharmacol Rep; 2010; 62(1):1-14. PubMed ID: 20360611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Huntington's disease: clinical and molecular genetics].
    Warita H; Shiro Y; Kashihara K; Abe K
    Nihon Rinsho; 1999 Apr; 57(4):896-9. PubMed ID: 10222786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse Models of Huntington's Disease.
    Farshim PP; Bates GP
    Methods Mol Biol; 2018; 1780():97-120. PubMed ID: 29856016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in Huntington's disease.
    Gutekunst CA; Norflus F; Hersch SM
    Curr Opin Neurol; 2000 Aug; 13(4):445-50. PubMed ID: 10970063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-dependent and tissue-specific CAG repeat instability occurs in mouse knock-in for a mutant Huntington's disease gene.
    Ishiguro H; Yamada K; Sawada H; Nishii K; Ichino N; Sawada M; Kurosawa Y; Matsushita N; Kobayashi K; Goto J; Hashida H; Masuda N; Kanazawa I; Nagatsu T
    J Neurosci Res; 2001 Aug; 65(4):289-97. PubMed ID: 11494364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Huntington's disease: from molecular pathogenesis to clinical treatment.
    Ross CA; Tabrizi SJ
    Lancet Neurol; 2011 Jan; 10(1):83-98. PubMed ID: 21163446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.
    Li JY; Popovic N; Brundin P
    NeuroRx; 2005 Jul; 2(3):447-64. PubMed ID: 16389308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.
    Chang R; Liu X; Li S; Li XJ
    Drug Des Devel Ther; 2015; 9():2179-88. PubMed ID: 25931812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.
    Jin J; Peng Q; Hou Z; Jiang M; Wang X; Langseth AJ; Tao M; Barker PB; Mori S; Bergles DE; Ross CA; Detloff PJ; Zhang J; Duan W
    Hum Mol Genet; 2015 May; 24(9):2508-27. PubMed ID: 25609071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant huntingtin can paradoxically protect neurons from death.
    Zuchner T; Brundin P
    Cell Death Differ; 2008 Mar; 15(3):435-42. PubMed ID: 17975550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.
    Valencia A; Reeves PB; Sapp E; Li X; Alexander J; Kegel KB; Chase K; Aronin N; DiFiglia M
    J Neurosci Res; 2010 Jan; 88(1):179-90. PubMed ID: 19642201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.